Committee Approval Date: May 9, 2014 Next Review Date: May 2015
|
|
- Baldric Patterson
- 5 years ago
- Views:
Transcription
1 Medication Policy Manual Policy No: dru180 Topic: Promacta, eltrombopag Date of Origin: May 8, 2009 Committee Approval Date: May 9, 2014 Next Review Date: May 2015 Effective Date: June 1, 2014 IMPTANT REMINDER This Medical Policy has been developed through consideration of medical necessity, generally accepted standards of medical practice, and review of medical literature and government approval status. Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. The purpose of medical policy is to provide a guide to coverage. Medical Policy is not intended to dictate to providers how to practice medicine. Providers are expected to exercise their medical judgment in providing the most appropriate care. Description Eltrombopag (Promacta ) is an oral medication used to increase platelets. dru180.5 Page 1 of 9
2 Policy/Criteria I. Most contracts require prior authorization of eltrombopag prior to coverage. Eltrombopag may be considered medically necessary when criteria A or B are met. A. A diagnosis of chronic idiopathic thrombocytopenia purpura (ITP), also known as immune thrombocytopenia, made by, or in consultation with, a hematologist. AND 1. Patient is at risk of spontaneous bleeding as demonstrated in chart notes by either one of the following criteria 1 or 2 below: a. Platelet count less than 20,000/mm 3. b. Platelet count less than 30,000/mm 3 accompanied by symptoms of bleeding. AND 2. Treatment with at least one the following ITP treatments was ineffective or not tolerated: a. Adequate course of systemic corticosteroids (e.g., prednisone 1 to 2 mg/kg for 2 to 4 weeks, or pulse dexamethasone 40 mg daily for 4 days). b. Immunoglobulin therapy. c. Splenectomy. B. The member has thrombocytopenia associated with hepatitis C (HCV) and is unable to initiate or maintain interferon (IFN) therapy due to platelet count less than 75,000/mm 3, and a Child-Pugh level A (score 5-6). (See Appendix B) II. Administration, Quantity Limitations, and Authorization Period A. RegenceRx considers eltrombopag to be a self-administered medication. B. When prior authorization is approved, eltrombopag may be authorized for an initial period of 12 weeks. dru180.5 Page 2 of 9
3 C. When prior authorization is approved, eltrombopag may be authorized in quantities of up to one tablet per day, 1. Not to exceed 75 mg per day for treatment of chronic ITP 2. Not to exceed 100 mg per day for the treatment of thrombocytopenia associated with HCV. D. Continued authorization or re-authorization (after the initial 12 week period) shall be reviewed at least every six months to confirm that current medical necessity criteria are met and that the medication is effective: 1. For chronic ITP: the patient s recent (within the last 90 days) platelet count is either: a. Equal to or greater than 30,000/mm 3 but not more than 150,000/mm 3. b. Less than 30,000/mm 3 but platelet counts have increased from baseline accompanied with a resolution of previous bleeding. 2. For thrombocytopenia associated with HCV: The patient remains on interferon/ribavirin therapy and platelet count is less than 400,000/ mm 3. III. Eltrombopag is considered investigational when used for all other conditions, including, but not limited to: A. Acute thrombocytopenia. B. Low platelet counts secondary to other conditions or diseases (including, but not limited to, cancer, HIV, and myelodysplastic syndrome). C. Drug-induced thrombocytopenia [e.g., chemotherapy, heparin (HIT)]. [1] D. Thrombocytopenia secondary to disseminated intravascular coagulation, hemangiomas, or platelet loss (massive bleeding). E. Thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS). F. In combination with direct-acting antivirals, such as HCV protease inhibitors or polymerase inhibitors, including but not limited to telaprevir (Incivek), boceprevir (Victrelis ), simeprevir (Olysio) or sofosbuvir (Sovaldi). G. In patients with evidence of decompensated liver disease with Child-Pugh score > 6 (class B and C), history of ascites, or hepatic encephalopathy. H. Thrombocytopenia associated with chronic liver disease (CLD), other than for initiation of HCV interferon therapy. dru180.5 Page 3 of 9
4 Position Statement Summary - Eltrombopag is a thrombopoietin (TPO) receptor agonist, used to increase platelet production in patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. [2,3] - It has only been studied in patients for whom traditional treatments have been ineffective. Steroids and/or splenectomy are considered first-line treatments of choice for chronic ITP. Other treatments include immune globulin therapy (IVIG), WinRho, rituximab, danazol, chemotherapy (e.g., cyclophosphamide, vincristine) and azathioprine. [4] - A normal platelet count in a healthy person is between 150,000 and 400,000/mm 3. The goal of treatment for chronic ITP should be to maintain a safe platelet count to decrease risks for bleeding, not to achieve a normal platelet count. [4] - Risk of spontaneous bleeding increases as platelet counts drops below 20,000/mm 3. [4] - Considering the slow time to response of TPO receptor agonists and frequent platelet lability in refractory ITP patients, ongoing use of eltrombopag may be indicated for patients with platelets well above the critical threshold, such as over 30,000 but less than 150,000/mm 3. - Due to risk of rare but serious side effects and uncertain long term benefit, eltrombopag should only be reserved for very refractory patients when other treatments options have been ineffective. - Eltrombopag is also used to treat thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. Safety and efficacy of eltrombopag has not been established for use in combination with direct-acting antivirals, such as protease inhibitors or polymerase inhibitors. [2] - Eltrombopag may be covered in doses up to 75 mg per day for treatment of ITP and up to 100 mg per day for treatment of thrombocytopenia associated with HCV. Clinical Efficacy Chronic ITP - Eltrombopag has been proven in clinical studies to be more effective for increasing platelets than placebo. [2,3,5] Eltrombopag may increase platelet counts; however, its effectiveness past 6 months is uncertain. Because the risk of bleeding is only prominent when platelet count drops below 20,000/mm 3, it is difficult to quantify the clinical benefit of treatment when half of the patients in the studies had platelet count above 20,000/mm 3 at baseline. dru180.5 Page 4 of 9
5 - It is uncertain whether the increase in platelets with eltrombopag is sustainable and whether eltrombopag decreases long-term rate of bleeding episodes or other complications in patients with chronic ITP. Low-certainty evidence from one 80-week open-label study in 207 patients with chronic ITP suggests that the effectiveness of eltrombopag may decrease significantly over time. At week 52, only 2 out of 207 patients were able to maintain platelet count >50,000/mm 3 continuously. [2,3] - Effect on overall survival is unknown, given the lack of evidence. [3] - Standard of care therapies are effective for many patients with chronic ITP. * Around one-third of patients may expect a long-term response from treatment with an oral corticosteroid. Corticosteroids should be rapidly tapered and stopped in patients who fail to respond after 4 weeks. [6] * Up to two-thirds of patients with ITP who undergo splenectomy may achieve a normal platelet count, which is often sustained with no additional therapy. [4,6] - There are no studies evaluating the efficacy of eltrombopag compared to other refractory ITP treatment options, such as romiplostim (Nplate). Trials of eltrombopag were conducted in patients refractory to standard treatments, predominantly corticosteroids, immunoglobulins, rituximab, cytotoxic therapies, danazol, and azathioprine, as well as splenectomy. [2] - Guidelines support the use of eltrombopag in chronic ITP refractory to standard therapies and rescue therapies. [4,5] Thrombocytopenia associated with Hepatitis C [2] - Two randomized-controlled studies for the treatment of thrombocytopenia in adult patients with chronic hepatitis C compare eltrombopag to placebo. Eltrombopag was administered in combination with pegylated interferon and ribavirin for up to 48 weeks. The primary efficacy endpoint for both trials was sustained virologic response (SVR) defined as the percentage of patients with undetectable HCV-RNA at 24 weeks after completion of antiviral treatment. The median time to achieve the target platelet count 90 x 10 9 /L was approximately 2 weeks. Ninety-five percent of patients were able to initiate interferon therapy. In both trials, a significantly greater proportion of patients treated with eltrombopag achieved SVR. - Eltrombopag was only studied in patients trying to receive interferon therapy. * There is no data on the safety and efficacy of eltrombopag in HCV patients on directacting antivirals, such as HCV protease inhibitors or polymerase inhibitors, including but not limited to telaprevir (Incivek), boceprevir (Victrelis), simeprevir (Olysio) or sofosbuvir (Sovaldi). - Eltrombopag doses should be lowered when platelet levels are between 200,000 and 400, 000/mm 3 and stopped when platelets are over 400,000/m 3. [2] dru180.5 Page 5 of 9
6 * There is insufficient evidence to support the use of eltrombopag in patients with thrombocytopenia associated with chronic liver disease (CLD), in the absence of trying to initiate and maintain interferon therapy for HCV. This includes CLD patients with liver failure and/or cirrhosis and patients undergoing an invasive procedure. [7,8] INVESTIGATIONAL USES - Although eltrombopag has been studied in a variety of other conditions, including but not limited to the conditions listed below, there is insufficient evidence to support its use in those settings. Larger, well-designed trials are needed to confirm preliminary results. [9] Acute thrombocytopenia Low platelet counts secondary to other conditions or diseases, including, but not limited to, cancer, HIV, aplastic anemia, and myelodysplastic syndrome (MDS). [10,11] Drug-induced thrombocytopenia [e.g., chemotherapy, heparin (HIT)] Thrombocytopenia secondary to disseminated intravascular coagulation, hemangiomas, or platelet loss (massive bleeding) Thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS) Safety [2] - Prescribing information contains a boxed warning regarding risk of hepatotoxicity. There is an increased risk of hepatic decompensation when used in combination with peginterferon and ribavirin in patients with hepatitis C. Existing liver abnormalities may preclude the use of eltrombopag in many hepatitis C patients. Careful liver function test (LFT) monitoring is recommended. - Patients with chronic liver disease require lower initial dose due to increased risk for thromboembolic events (specifically portal vein thrombosis). - Uncommon but serious side effects include: * Bone marrow changes: eltrombopag increases the risk for reticulin deposition within the bone marrow. Clinical studies have not ruled out the possibility that reticulin and other fiber deposition may result in bone marrow fibrosis with cytopenias. * Worsening low blood platelet count: discontinuation of eltrombopag may result in worsened thrombocytopenia than was present prior to eltrombopag therapy and increased risk for bleeding. * High platelet counts and increased risk of blood clots: eltrombopag may increase platelet counts to a level that produces thrombotic/thromboembolic complications. dru180.5 Page 6 of 9
7 * Worsening hematologic conditions: romiplostim may increase the risk for hematological malignancies, especially in patients with myelodysplastic syndrome. - More common adverse reactions are nausea, vomiting, menorrhagia, myalgia, paresthesia, cataract, dyspepsia, ecchymosis, thrombocytopenia, increased ALT/AST and conjunctival hemorrhage. - Drug interactions and the overall safety of eltrombopag have not been evaluated in patients receiving direct-acting antivirals for hepatitis C, such as boceprevir (Victrelis) and telaprevir (Incivek). These medications are part of standard of care treatment for the most common HCV genotype (genotype 1). - Both thrombopoietin receptor agonists, eltrombopag and romiplostim, have a Risk Evaluation and Mitigation Strategy (REMS) program for the risk of bone marrow fibrosis, thromboembolic events, and hematologic malignancy. Risk for hepatotoxicity is also included in the eltrombopag program, and risk for worsening thrombocytopenia and bleeding after treatment discontinuation is included in the romiplostim program. [12] Dosing [2] - The initial dose of eltrombopag for most chronic ITP patients is 50 mg once daily. Maximum dose is 75 mg daily and adjusted based on clinical response (platelet count and bleeding). - Initial response to romiplostim for ITP is usually seen within 7 to 28 days, with a peak response in 14 to 90 days. [4] - The initial dose of eltrombopag HCV-associated thrombocytopenia is 25 mg once daily. Maximum dose is 100 mg daily and adjusted based on response of platelet count, to allow initiation of antiviral therapy. - The safety and effectiveness of higher doses have not been established. dru180.5 Page 7 of 9
8 Appendix A: American Society of Hematology Criteria for the Diagnosis of Chronic Immune Thrombocytopenic Purpura : Diagnosis of Exclusion [2] - History compatible with the diagnosis of chronic ITP - Normal physical examination findings except for signs of thrombocytopenia (petechiae, purpura, or mucosal bleeding); no adenopathy or splenomegaly - Complete blood count showing isolated thrombocytopenia with large platelets but no anemia unless bleeding or immune hemolysis is present - Bone marrow examination showing normal or increased numbers of megakaryocytes (not required for diagnosis unless unusual manifestation or age >60 yr.) - No clinical or laboratory evidence for other causes of thrombocytopenia Appendix B: Child-Pugh Classification Of Severity Of Liver Disease Child-Pugh Classification Points A: well-compensated disease 5 to 6 B: significant functional compromise 7 to 9 C: decompensated disease 10 to 15 Points Assigned Parameter Ascites Absent Slight Moderate Bilirubin (mg/dl) < 2 2 to 3 > 3 Albumin (g/dl) > to 3.5 < 2.8 Prothrombin Time Seconds over control 1 to 3 4 to 6 >6 INR < to 2.3 > 2.3 Encephalopathy None Grade 1 to 2 Grade 3 to 4 dru180.5 Page 8 of 9
9 Cross References Immune Globulin Replacement Therapy (IVIG, SQ), RegenceRx Medication Policy Manual, Policy No. dru020 Rituxan, rituximab, RegenceRx Medication Policy Manual, Policy No. dru214 Nplate, romiplostim, RegenceRx Medication Policy Manual, Policy No. dru162 References 1. Kellum, A, Jagiello-Gruszfeld, A, Bondarenko, IN, Patwardhan, R, Messam, C, Mostafa Kamel, Y. A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors. Curr Med Res Opin Oct;26(10): PMID: Promacta (eltrombopag) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; February Zeng, Y, Duan, X, Xu, J, Ni, X. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura. Cochrane Database Syst Rev. 2011(7):CD PMID: Neunert, C, Lim, W, Crowther, M, et al. The American Society of Hematology (ASH) 2011 evidence-based practice guideline for immune thrombocytopenia. Blood Apr 21;117(16): PMID: National Institute for Health and Clinical Evidence (NICE). NICE technology appraisal 293 (TA293). Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura(itp). Issued: July [cited March 19, 2014]; Available from: 6. British Committee for Standards in Haematology General Haematology Task, F. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol Feb;120(4): PMID: Afdhal, NH, Giannini, EG, Tayyab, G, et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med Aug 23;367(8): PMID: Aguilar, C. Potential usefulness of thrombopoietin receptor agonists in haemophiliacs with thrombocytopaenia due to chronic liver disease. Blood Coagul Fibrinolysis Apr;24(3): PMID: Clinicaltrials.gov. [cited (updated periodically)]; Available from: Marsh, JC, Kulasekararaj, AG. Management of the refractory aplastic anemia patient: what are the options? Blood Nov 21;122(22): PMID: Townsley, DM, Desmond, R, Dunbar, CE, Young, NS. Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes. International journal of hematology Jul;98(1): PMID: Nplate (romiplostim) for subcutaneous injection [package insert]. thousand Oaks, CA: Amgen, Inc.; February 2014 dru180.5 Page 9 of 9
eltrombopag (Promacta )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationPromacta (eltrombopag)
Promacta (eltrombopag) Policy Number: 5.01.542 Last Review: 5/2018 Origination: 6/2013 Next Review: 5/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Promacta
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Romiplostim Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date... 12/15/2017 Next
More informationTopic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015
Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014
More informationPROMACTA (eltrombopag olamine) oral tablet and oral suspension
PROMACTA (eltrombopag olamine) oral tablet and oral suspension Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit
More informationPromacta. Promacta (eltrombopag) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.15 Subject: Promacta Page: 1 of 6 Last Review Date: September 15, 2017 Promacta Description Promacta
More informationExpert Review: Updates in Immune Thrombocytopenia. Reference Slides
Expert Review: Updates in Immune Thrombocytopenia Reference Slides Immune Thrombocytopenia (ITP): Overview ITP causality 1,2 Suboptimal platelet production Dysregulated adaptive immune system Increased
More informationThrombopoietin Receptor Agonists Prior Authorization with Quantity Limit Program Summary
Thrombopoietin Receptor Agonists Prior Authorization with Quantity Limit Program Summary Thrombopoietin Receptor Agonists Prior Authorization with Quantity Limit OBJECTIVE The intent of the prior authorization
More informationPromacta. Promacta (eltrombopag) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.15 Subject: Promacta Page: 1 of 6 Last Review Date: September 20, 2018 Promacta Description Promacta
More informationTreatment pathway for adult patients with immune (idiopathic) thrombocytopenic purpura (ITP)
Prescribing Clinical Network Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG) Crawley and Horsham & Mid-Sussex CCG Treatment pathway for adult
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Promacta) Reference Number: CP.PHAR.180 Effective Date: 03.01.16 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important
More informationScottish Medicines Consortium
Scottish Medicines Consortium romiplostim, 250 microgram vial of powder for solution for subcutaneous injection (Nplate ) No. (553/09) Amgen 08 May 2009 (Issued 4 September 2009) The Scottish Medicines
More informationClinical Policy: Eltrombopag (Promacta) Reference Number: ERX.SPA.71 Effective Date:
Clinical Policy: (Promacta) Reference Number: ERX.SPA.71 Effective Date: 10.01.16 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationPegylated Interferon Agents for Hepatitis C
Applicable X X X X X X X Pegylated Interferon Agents for Hepatitis C Override(s) Prior Authorization Quantity Limit Initial for Monotherapy or Combination with Ribavirin based on Genotype, Status, or Co-Infection
More informationQUICK REFERENCE Clinical Practice Guideline on the Evaluation and Management of Immune Thrombocytopenia (ITP)
QUICK REFERENCE 2011 Clinical Practice Guideline on the Evaluation and Management of Immune Thrombocytopenia (ITP) Presented by the American Society of Hematology, adapted from: The American Society of
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Promacta (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization MERC CARE (MEDICAID) Promacta (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax
More informationTavalisse (fostamatinib disodium hexahydrate)
Tavalisse (fostamatinib disodium hexahydrate) Policy Number: 5.01.661 Last Review: 07/2018 Origination: 07/2018 Next Review: 07/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide
More information2. Does the patient have a diagnosis of chronic idiopathic thrombocytopenic purpura (ITP)?
Pharmacy Prior Authorization MERC CARE (MEDICAID) Promacta (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax
More informationCynthia Fata, MD, MSPH 6/23/15
Cynthia Fata, MD, MSPH 6/23/15 Clinical case presentation Introduction to thrombopoietin Development of thrombopoietic agents Clinical Indications Eltrombopag use in aplastic anemia Future uses 33 yo F
More informationAcute Immune Thrombocytopenic Purpura (ITP) in Childhood
Acute Immune Thrombocytopenic Purpura (ITP) in Childhood Guideline developed by Robert Saylors, MD, in collaboration with the ANGELS team. Last reviewed by Robert Saylors, MD September 22, 2016. Key Points
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1146-7 Program Prior Authorization/Notification Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 10/2014, 2/2015,
More informationThrombocytopenia: a practial approach
Thrombocytopenia: a practial approach Dr. med. Jeroen Goede FMH Innere Medizin, Medizinische Onkologie, Hämatologie FAMH Hämatologie Chefarzt Hämatologie Kantonsspital Winterthur Outline Introduction and
More informationMost Common Hemostasis Consults: Thrombocytopenia
Most Common Hemostasis Consults: Thrombocytopenia Cindy Neunert, MS MSCS Assistant Professor, Pediatrics CUMC Columbia University TSHNA Meeting, April 15, 2016 Financial Disclosures No relevant financial
More informationScottish Medicines Consortium
Scottish Medicines Consortium eltrombopag, 25mg and 50mg film-coated tablets (Revolade ) No. (625/10) GlaxoSmithKline UK 09 July 2010 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Epclusa) Reference Number: CP.CPA.286 Effective Date: 11.01.16 Last Review Date: 08.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationThe ITP Patient Advocate
The ITP Patient Advocate A Resource for Your Journey With Chronic ITP Visit nplate.com for more information Issue Two Medical News About Nplate This issue looks at a recent 1-year Nplate medical study
More informationENABLE 1 Study. To evaluate the safety and tolerability of eltrombopag Primary efficacy outcome: proportion of patients who achieve SVR
Final Results of ENABLE 1, a Phase 3, Multicenter Study of as an Adjunct for Antiviral Treatment of Hepatitis C Virus -Related Chronic Liver Disease Associated With Thrombocytopenia N. Afdhal; G. Dusheiko;
More informationDiagnosis and Management of Immune Thrombocytopenias. Thomas L. Ortel, M.D., Ph.D. Duke University Medical Center 2 November 2016
Diagnosis and Management of Immune Thrombocytopenias Thomas L. Ortel, M.D., Ph.D. Duke University Medical Center 2 November 2016 Disclosures Research support: NIH, CDC, Eisai, Pfizer, Daiichi Sankyo, GlaxoSmithKline,
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 16 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Harvoni) Reference Number: CP.CPA.175 Effective Date: 11.01.16 Last Review Date: 08.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationClinical Policy: Glecaprevir/Pibrentasvir (Mavyret) Reference Number: HIM.PA.SP36 Effective Date: Last Review Date: 06.18
Clinical Policy: (Mavyret) Reference Number: HIM.PA.SP36 Effective Date: 08.01.17 Last Review Date: 06.18 Line of Business: HIM Revision Log See Important Reminder at the end of this policy for important
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
DIRECT ACTING ANTIVIRAL AGENTS FOR HEPATITIS C VIRUS (HCV): DAKLINZA (daclatasvir) oral tablet EPCLUSA (velpatasvir, sofosbuvir) oral tablet HARVONI (ledipasvir, sofosbuvir) oral tablet MAVYRET (glecaprevir,
More informationthrombopoietin receptor agonists and University of Washington January 13, 2012
Tickle me eltrombopag: thrombopoietin receptor agonists and the regulation of platelet production Manoj Menon University of Washington January 13, 2012 Outline Clinical case Pathophysiology of ITP Therapeutic
More informationEvolution of clinical guidelines for ITP: Role of Romiplostim
Slovenian Haematological Society 16 April 2010, Podčetrtek Evolution of clinical guidelines for ITP: Role of Romiplostim Dr. Roberto Stasi Department of Haematology St George's Hospital London Is there
More informationClinical Policy Bulletin: Romiplostim (Nplate)
Romiplostim (Nplate) Page 1 of 8 Aetna Better Health 2000 Market Suite Ste. 850 Philadelphia, PA 19103 AETNA BETTER HEALTH Clinical Policy Bulletin: Romiplostim (Nplate) Number: 0768 Policy Aetna considers
More informationCommittee Approval Date: May 9, 2014 Next Review Date: May 2015
Medication Policy Manual Policy No: dru248 Topic: Benlysta, belimumab Date of Origin: May 13, 2011 Committee Approval Date: May 9, 2014 Next Review Date: May 2015 Effective Date: June 1, 2014 IMPORTANT
More informationClinical Policy: Simeprevir (Olysio) Reference Number: CP.CPA.289 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Olysio) Reference Number: CP.CPA.289 Effective Date: 11.01.16 Last Review Date: 08.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationPlatelet Disorders. By : Saja Al-Oran
Platelet Disorders By : Saja Al-Oran Introduction The platelet arise from the fragmentation of the cytoplasm of megakaryocyte in the bone marrow. circulate in the blood as disc-shaped anucleate particles
More information(eltrombopag) in chronic hepatitis C-associated thrombocytopenia (HCVaT)
All materials supplied by the Global Oncology must be subject to local Medical and/or Regulatory review and approval prior to external distribution. Safety Guide for REVOLADE (eltrombopag) in chronic hepatitis
More informationSupplemental Appendix. 1. Protocol Definition of Sustained Virologic Response. A patient has a sustained virologic response if:
Supplemental Appendix 1. Protocol Definition of Sustained Virologic Response A patient has a sustained virologic response if: 1. The patient is a responder at the end of treatment and all subsequent planned
More informationMonitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy
Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy WV ECHO August 10, 2017 Selection of patients for HCV treatment Despite current guidance to treat everyone,
More informationDr Kannan S Consultant Hematologist Sahyadri Speciality Hospital, Pune K E M Hospital, Pune
IMMUNE THROMBOCYTOPENIA Dr Kannan S Consultant Hematologist Sahyadri Speciality Hospital, Pune K E M Hospital, Pune ITP Megakaryocytes Definition of ITP Primary immune thrombocytopenia Platelet count
More information2017 United Healthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2055-10 Program Prior Authorization/Medical Necessity Medication Olysio (simeprevir) P&T Approval Date 4/2015, 11/2015, 8/2016,
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2052-10 Program Prior Authorization/Medical Necessity Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 4/2015, 8/2015,
More informationClinical Policy: Daclatasvir (Daklinza) Reference Number: CP.CPA.283 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Daklinza) Reference Number: CP.CPA.283 Effective Date: 11.01.16 Last Review Date: 08.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for
More informationDrug Class Review: Thrombocytopenia
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-2596
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir ) Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir)
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Olysio (simeprevir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/9/2014 1. Indications Drug Name: Olysio
More informationThe Role for Eltrombopag (Promacta) in the Treatment of HepC-Related Thrombocytopenia
The Role for Eltrombopag (Promacta) in the Treatment of HepC-Related Thrombocytopenia N. Afdhal M.D Beth Israel Deaconess Liver Center Harvard Medical School MLV Conference Call September 7, 2011 4:30
More informationVosevi (sofosbuvir/velpatasvir/voxilaprevir)
Vosevi (sofosbuvir/velpatasvir/voxilaprevir) Policy Number: 5.01.646 Last Review: 10/2017 Origination: 10/2017 Next Review: 11/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide
More informationSecond line therapy for ITP should be TPO agonists. Nichola Cooper Imperial Health Care NHS Trust
Second line therapy for ITP should be TPO agonists Nichola Cooper Imperial Health Care NHS Trust COHEM 2012 Antiplatelet antibodies Platelet count after infusion with patient plasma Hours Days T cells
More informationFor platelet control as individual as you
For platelet control as individual as you Explore the possibilities of Immune Thrombocytopenic Purpura (ITP) treatment. Important Risk Information WARNING: INTRAVASCULAR HEMOLYSIS (IVH) Intravascular hemolysis
More informationSafety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus
Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus JEFFREY NADELSON MD, ALAN EPSTEIN MD, THOMAS SEPE MD BOSTON UNIVERSITY SCHOOL OF MEDICINE ROGER WILLIAMS MEDICAL
More informationNplate (romiplostim) For subcutaneous injection Initial U.S. Approval: 2008
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Nplate safely and effectively. See full prescribing information for Nplate. Nplate (romiplostim)
More informationSovaldi (sofosbuvir)
Market DC Sovaldi (sofosbuvir) Override(s) Prior Authorization Quantity Limit Approval Duration Based on Genotype, Treatment status, Cirrhosis status, or Ribavirin Eligibility status **IN, SC, WA Medicaid
More informationRevolade Approved in EU as First in Class Therapy for Children Aged 1 Year and Above with Chronic ITP
April 7, 2016 Revolade Approved in EU as First in Class Therapy for Children Aged 1 Year and Above with Chronic ITP Revolade is marketed as Promacta in the United States EU approval of Revolade expands
More informationStick or twist management options in hepatitis C
Stick or twist management options in hepatitis C Dr. Chris Durojaiye & Dr. Matthijs Backx SpR Microbiology and Infectious Diseases University Hospital of Wales, Cardiff Patient history 63 year old female
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir) PHARMACY PRI AUTHIZATION Hepatitis C Clinical Guideline Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir) Harvoni
More informationHemostatic System - general information
PLATELET DISORDERS Hemostatic System - general information Normal hemostatic system vessel wall circulating blood platelets blood coagulation and fibrynolysis Bleeding Diathesis inherited or acquired defects
More informationUse of TPO mimetics for Indications Other Than ITP
Use of TPO mimetics for Indications Other Than ITP Mazyar Shadman, MD, MPH Discussant: Siobán Keel, MD Hematology Fellows Conference June 28, 2013 Thrombopoietin (TPO) and other c mpl ligands TPO mimetics
More informationTreatment of Hepatitis C with ombitasvir, paritaprevir, and ritonavir (Technivie )
Treatment of Hepatitis C with ombitasvir, paritaprevir, and ritonavir (Technivie ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis B / Hepatitis C Peg-interferon Page 1 of 20 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis B / Hepatitis C Peg-interferon Hepatitis
More informationIntron A (interferon alfa-2b) with ribavirin, (Moderiba, Rebetol, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.06 Subject: Intron A Ribavirin Page: 1 of 6 Last Review Date: March 18, 2016 Intron A Ribavirin Description
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1231-1 Program Prior Authorization/Notification Medication Mavyret (glecaprevir/pibrentasvir) P&T Approval Date 9/2017 Effective
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Daklinza) Reference Number: HIM.PA.SP27 Effective Date: Last Review Date: 01/17 Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important Reminder
More informationAppendix to Notification Letter for rituximab and eltrombopag dated 20 February 2014
Appendix to Notification Letter for rituximab and eltrombopag dated 20 February 2014 The notification letter which contains details of the decision to widen the restriction criteria for rituximab and eltrombopag
More informationDavid Zaccardelli, PharmD Chief Executive Officer. J.P. Morgan 37 th Annual Healthcare Conference January 8, 2019
David Zaccardelli, PharmD Chief Executive Officer J.P. Morgan 37 th Annual Healthcare Conference January 8, 2019 Disclaimer Certain information contained in this presentation relates to or is based on
More informationCommittee Approval Date: December 12, 2014 Next Review Date: December 2015
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationClinical Policy: Daclatasvir (Daklinza) Reference Number: HIM.PA.SP27 Effective Date: Last Review Date: 06.18
Clinical Policy: (Daklinza) Reference Number: HIM.PA.SP27 Effective Date: 01.01.17 Last Review Date: 06.18 Line of Business: HIM Revision Log See Important Reminder at the end of this policy for important
More informationIOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road 5)
IOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road 5) 974-3131 -866-626-0216 Brett Faine, Pharm.D. Larry Ambroson, R.Ph. Brian Couse, M.D. Date: February 10, 2015 Mark Graber, M.D., FACEP,
More informationClinical Policy: Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi) Reference Number: GA.PMN.25 Product: Medicaid Effective Date: 9/17
Clinical Policy: Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi) Reference Number: GA.PMN.25 Product: Medicaid Effective Date: 9/17 Last Review Date: 9/17 Revision Log See Important Reminder at the end of
More informationREVOLADE TABLETS AND POWDER FOR ORAL SUSPENSION
PRODUCT INFORMATION REVOLADE TABLETS AND POWDER FOR ORAL SUSPENSION NAME OF THE MEDICINE Active ingredient: Chemical name: Chemical structure: eltrombopag olamine 3'-{(2Z)-2-[1-(3,4-dimethyl-phenyl)-3-methyl-5-oxo-1,5-dihydro-4Hpyrazol-4-ylidene]hydrazino}-2'-hydroxy-3-biphenyl
More informationRemissions after long term use of romiplostim for immune thrombocytopenia
Published Ahead of Print on September 1, 2016, as doi:10.3324/haematol.2016.151886. Copyright 2016 Ferrata Storti Foundation. Remissions after long term use of romiplostim for immune thrombocytopenia by
More informationPediatric Immune Thrombocytopenia (ITP) Cindy E. Neunert MD, MSCS Associate Professor, Pediatrics Columbia University Medical Center New York, NY
Pediatric Immune Thrombocytopenia (ITP) Cindy E. Neunert MD, MSCS Associate Professor, Pediatrics Columbia University Medical Center New York, NY Objectives Review the 2011 American Society of Hematology
More informationTreatment of Hepatitis C with sofosbuvir/ledipasvir (Harvoni )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationASH Draft Recommendations for Immune Thrombocytopenia
ASH Draft Recommendations for Immune Thrombocytopenia INTRODUCTION American Society of Hematology (ASH) guidelines are based on a systematic review of available evidence. Through a structured process,
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationpregnant patients in the Nplate pregnancy registry by calling Adjust weekly dose by increments of 1 mcg/kg to achieve and maintain a
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Nplate safely and effectively. See full prescribing information for Nplate. Nplate (romiplostim)
More informationPRODUCT MONOGRAPH. Eltrombopag Tablets. 25 mg, 50 mg and 75 mg Eltrombopag (as Eltrombopag Olamine) Thrombopoietin Receptor Agonist
PRODUCT MONOGRAPH Pr REVOLADE Eltrombopag Tablets 25 mg, 50 mg and 75 mg Eltrombopag (as Eltrombopag Olamine) Thrombopoietin Receptor Agonist Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval,
More informationTechnology appraisal guidance Published: 27 April 2011 nice.org.uk/guidance/ta221
Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura Technology appraisal guidance Published: 27 April 2011 nice.org.uk/guidance/ta221 NICE 2018. All rights reserved. Subject
More informationSUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other TELAPREVIR INCIVEK 37629 This drug requires a written request for prior authorization. All requests for hepatitis C medications require review by a pharmacist prior
More informationIt is the policy of health plans affiliated with Centene Corporation that Mavyret is medically necessary when the following criteria are met:
Clinical Policy: (Mavyret) Reference Number: CP.CPA.285 Effective Date: 08.15.17 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationPROMACTA (eltrombopag) tablets, for oral use PROMACTA (eltrombopag) for oral suspension Initial U.S. Approval: 2008
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PROMACTA safely and effectively. See full prescribing information for PROMACTA. PROMACTA (eltrombopag)
More informationCase Report Myelofibrosis Associated with Romiplostim Treatment in a Patient with Immune Thrombocytopenia
Volume 2012, Article ID 318597, 4 pages doi:10.1155/2012/318597 Case Report Myelofibrosis Associated with Romiplostim Treatment in a Patient with Immune Thrombocytopenia Maria Fernanda Gonzalez and Jonathan
More information2018 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1127-9 Program Prior Authorization/Notification Medication Sovaldi (sofosbuvir) P&T Approval Date 2/2014, 4/2014, 5/2014, 8/2014,
More informationEltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205)
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Final appraisal determination Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205) This guidance
More informationMedication Policy Manual. Topic: Juxtapid, lomitapide Date of Origin: May 16, 2013
Medication Policy Manual Policy No: dru302 Topic: Juxtapid, lomitapide Date of Origin: May 16, 2013 Committee Approval Date: March 13, 2015 Next Review Date: March 2016 Effective Date: April 1, 2015 IMPORTANT
More informationThere are two main causes of a low platelet count
Thrombocytopenia Thrombocytopenia is a condition in which a person's blood has an unusually low level of platelets Platelets, also called thrombocytes, are found in a person's blood along with red blood
More informationNPLATE (romiplostim) for injection, for subcutaneous use Initial U.S. Approval: 2008
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NPLATE safely and effectively. See full prescribing information for NPLATE. NPLATE (romiplostim)
More informationOlysio Pegasys Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.28 Subject: Olysio Pegasys Ribavirin Page: 1 of 7 Last Review Date: March 18, 2016 Olysio Pegasys
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2132-1 Program Prior Authorization/Medical Necessity Medication Mavyret (glecaprevir/pibrentasvir) P&T Approval Date 9/2017 Effective
More informationBleeding Disorders.2 MS Abdallah Awidi Abbadi.MD. FRCP.FRCPath Feras Fararjeh MD
Bleeding Disorders.2 MS4.25.02.2019 Abdallah Awidi Abbadi.MD. FRCP.FRCPath Feras Fararjeh MD Email: abdalla.awidi@gmail.com Case 6: GT 18 yr old female was admitted with pallor, abdominal pain and gum
More informationHorizon Scanning Centre November Faldaprevir with BI for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688
Horizon Scanning Centre November 2012 Faldaprevir with BI 207127 for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688 This briefing is based on information available at the time of research
More informationHIV and Hepatitis C: Advances in Treatment
NORTHWEST AIDS EDUCATION AND TRAINING CENTER HIV and Hepatitis C: Advances in Treatment John Scott, MD, MSc Asst Professor University of Washington Presentation prepared & presented by: John Scott, MD,
More informationWhat should I discuss with my health care provider before taking eltrombopag?
1 of 6 6/10/2016 3:57 PM Generic Name: eltrombopag (el TROM boe pag) Brand Name: Promacta What is eltrombopag? Eltrombopag is a man-made form of a protein that increases production of platelets (blood-clotting
More informationHMO: Medical (provider setting); Rx (out patient) PPO/CDHP: Rx
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Epogen, Procrit (epoetin alfa, injection) Commercial HMO/PPO/CDHP
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PROMACTA safely and effectively. See full prescribing information for PROMACTA. PROMACTA (eltrombopag)
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 08/19/14 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:
RITUXAN (rituximab) Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline
More information